Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy

Bellone, Matteo; Caputo, Sara

doi:10.1007/978-3-030-16624-3_8

Cited by 3 publications

(2 citation statements)

References 325 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously reported that TPIN-SCs, despite their highly metastatic behavior (43), can be targeted both by innate and adaptive immune cells (44), but are also endowed with immunosuppressive activities (45). In particular, we have found that TPIN-SCs use the extracellular matrix protein Tenascin-C to dampen T cell activation (30,46), a mechanism that might favor their metastatic propensity.…”

Section: Gal-3 Favors Proliferation Spheroid Formation Tumorigenicimentioning

confidence: 99%

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is an extracellular matrix glycan-binding protein with several immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells (CSCs) is poorly investigated. Here, we show that prostate CSCs also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate (TRAMP) mice overexpress Gal-3. Gal-3 contributes to prostate CSC-mediated immune suppression because either Gal-3 silencing in CSCs, or co-culture of CSCs and T cells in the presence of the Gal-3 inhibitor N-Acetyl-D-lactosamine rescued T cell proliferation. N-Acetyl-D-lactosamine also rescued the proliferation of T cells in prostate-draining lymph nodes of TRAMP mice affected by prostate intraepithelial neoplasia. Additionally, Gal-3 impacted prostate CSC tumorigenic and metastatic potential in vivo, as Gal-3 silencing in prostate CSCs reduced both primary tumor growth and secondary invasion. Gal-3 was also found expressed in more differentiated prostate cancer cells, but with different intracellular distribution as compared to CSCs, which suggests different functions of Gal-3 in the two cell populations. In fact, the prevalent nuclear and cytoplasmic distribution of Gal-3 in prostate CSCs made them less susceptible to apoptosis, when compared to more differentiated prostate cancer cells, in which Gal-3 was predominantly intra-cytoplasmic. Finally, we found Gal-3 expressed in human and mouse prostate intraepithelial neoplasia lesions and in metastatic lymph nodes. All together, these findings identify Gal-3 as a key molecule and a potential therapeutic target already in the early phases of prostate cancer progression and metastasis.

show abstract

Section: Gal-3 Favors Proliferation Spheroid Formation Tumorigenicimentioning

confidence: 99%

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The normal prostate gland measures 3×3×5 cm, volume of 25 ml [7]. Traditionally, the prostate is divided into anatomical lobes (inferoposterior, inferolateral, superomedial, and anteromedial) [8].…”

Section: Introductionmentioning

confidence: 99%

Frequency of Ultrasound in Assessment of Prostate Gland in Different Age Groups

Hussain

Khan²,

Hasan³

et al. 2022

EJMED

View full text Add to dashboard Cite

The prostate gland is the main male accessory gland as it secretes fluid that nourishes and protects sperm. With age, the prostate can enlarge. As it surrounds part of the urethra, the enlarged prostate can squeeze the tube. This and some other pathologies of the prostate can cause different problems like urinary retention, impaired kidney feature, recurrent urinary tract infections, gross hematuria, and bladder calculi. This was a descriptive study with a sample size of 200 patients, performed at Gillani Ultrasound Center Lahore and The University Ultrasound Clinic Green Town Lahore from July till November 2021. Individuals of all ages above 23 years of age were diagnosed with all pathologies of the prostate. The patients with UTI, cystitis or bladder stone were not considered in this research. Transabdominal sonography was performed with the convex transducer of 3.5 - 5 MHz frequency. In this descriptive study, the total sample size of the study was 200 from which BPH was found in 142 Patients 71%, BPH with prostatic cyst was in 6 patients 3%, Prostatic calcification was in 14 patients 7%, BPH with prostatic calcification was in 11 patients 5.5%, Prostatic cancer was in 1 patient 0.5% and the prostatic cyst was in 26 patients that are 13% of the sample size. Ultrasound has been proven to diagnose early prostatic enlargement and other prostate-related pathologies, our study concluded that BPH is the most common pathology ranging between 50 to 60 years, and prostatic cyst and calcification were common in ages 23 to 35.

show abstract

Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies

Rahman,

Akter,

Ahmed

et al. 2024

Cancers

View full text Add to dashboard Cite

Castration-resistant prostate cancer (CRPC) remains a significant therapeutic challenge due to its resistance to standard androgen deprivation therapy (ADT). The emergence of androgen receptor splice variant 7 (AR-V7) has been implicated in CRPC progression, contributing to treatment resistance. Current treatments, including first-generation chemotherapy, androgen receptor blockers, radiation therapy, immune therapy, and PARP inhibitors, often come with substantial side effects and limited efficacy. Natural compounds, particularly those derived from herbal medicine, have garnered increasing interest as adjunctive therapeutic agents against CRPC. This review explores the role of AR-V7 in CRPC and highlights the promising benefits of natural compounds as complementary treatments to conventional drugs in reducing CRPC and overcoming therapeutic resistance. We delve into the mechanisms of action underlying the anti-CRPC effects of natural compounds, showcasing their potential to enhance therapeutic outcomes while mitigating the side effects associated with conventional therapies. The exploration of natural compounds offers promising avenues for developing novel treatment strategies that enhance therapeutic outcomes and reduce the adverse effects of conventional CRPC therapies. These compounds provide a safer, more effective approach to managing CRPC, representing a significant advancement in improving patient care.

show abstract

Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy

Cited by 3 publications

References 325 publications

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

Frequency of Ultrasound in Assessment of Prostate Gland in Different Age Groups

Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies

Contact Info

Product

Resources

About